Aptorum Group shares surge 15.56% intraday after announcing two abstracts accepted for CTAD 2025 conference on Alzheimer's research with DiamiR Biosciences.

Aptorum Group surged 15.56% intraday after announcing two abstracts accepted for presentation at the 2025 CTAD Alzheimer’s conference with DiamiR Biosciences. The studies highlight brain-enriched and inflammation-associated microRNA biomarkers for neurodegeneration, developed in collaboration with NYU and the University of Pennsylvania. The news, coupled with the pending merger between Aptorum and DiamiR, underscored progress in advancing diagnostic tools for Alzheimer’s, enhancing investor confidence in the company’s pipeline. The merger, expected to close in early 2026, further positioned Aptorum as a leader in neurodegenerative disease research, aligning with the stock’s sharp intraday gains.